(Other OTC:JETMF),(OTC US:JETMF),(Neo:JET.NE),(Neo:JET-B.NE),(Neo:JET),(Neo:JET-B), GAAP Net Income of $0.6 Million or $0.01 per Share; EBITDAR1 of $19.8 Million Generated Record Block Hours of 8,065 in Q2 MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) — Global Crossing Airlines Group, Inc. (Cboe CA: JET, Cboe CA: JET.B, OTCQB: JETMF) (the “Company” or “GlobalX”), the nation's fastest growing charter airline, […]
(NasdaqGM:HYPR), GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system–the Swoop(R) system–today announced second quarter 2025 financial results and provided a business update. “In the second quarter, we executed across
(NASDAQ:SSKN), HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update. Second Quarter
(NASDAQ:BRFH), Revenue Increased 11% Year-Over-Year to $1.6 Million for Second Quarter 2025 Achieved Gross Margin of 31% for Second Quarter 2025 New Co-Manufacturer Completes Equipment Installation at End of Second Quarter 2025 and Commences Increased Supply for Third Quarter 2025 Company Expects an Increase in Revenue and Gross Margin for the Second Half of 2025
(NASDAQ:CYCC),(NASDAQ:CYCCP), KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include:
(NASDAQ:TOI),(NASDAQ:TOIIW), CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended June 30, 2025. Daniel Virnich, CEO of TOI, commented, “We delivered another strong quarter with
(NASDAQ:ICU), Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolled Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) Positive survival results reported from QUELIMMUNE SAVE Surveillance Registry Webcast call today at 4:30 p.m. Eastern Time DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) — SeaStar
dLocal announces appointment of Chief Financial Officer GlobeNewswire August 13, 2025 MONTEVIDEO, Uruguay, Aug. 13, 2025 (GLOBE NEWSWIRE) — DLocal Limited (“dLocal”, “we”, “us”, and “our”) (NASDAQ:DLO), a technology – first payments platform, today announced the appointment of Guillermo Lopez Perez as Chief Financial Officer, who will join us in the next few months. Guillermo
(NASDAQ:TENX), Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or
(NYSE:COHR), FY25 REVENUE OF $5.81B, INCREASED 23% Y/Y FY25 GAAP GROSS MARGIN OF 35.2%, INCREASED 424 bps Y/Y; FY25 NON-GAAP GROSS MARGIN OF 37.9%, INCREASED 358 bps Y/Y FY25 GAAP LOSS OF $0.52, IMPROVED $1.32 Y/Y; FY25 NON-GAAP EPS OF $3.53, IMPROVED $2.32 Y/Y SAXONBURG, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: